Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Scandinavian Immunisation Advice Consulting AB
AB
Active
Org 5593211989
Köpmantorget 2
General medical practice activities · NACE 8621
Est. 2021
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
SEK 40K
-8% vs 2023
EBITDA margin
79.5%
-10% vs 2023
Equity ratio
79.1%
Financial strength
Net profit 2024
SEK 25K
-11% vs 2023
EBITDA — year on year
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2021
0M
0%
2022
0M
0%
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
SEK 40K
-8%
EBITDA
SEK 32K
-10%
Net profit
SEK 25K
-11%
Total assets
SEK 96K
+46%
Equity
SEK 76K
+50%
Employees
0
—
Company information
Legal name
Scandinavian Immunisation Advice Consulting AB
Org number
5593211989
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
7 juni 2021
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska erbjuda konsulttjänster rörande vacciner och dess användande och därmed förenlig verksamhet.
Contact
Address
Köpmantorget 2
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in General medical practice activities
Companies in Stockholm
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
0M
2024
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
0M
2024
Income statement
SEK thousands
Item
2021
2022
2023
2024
Revenue
0
12
44
40
Staff expenses
—
—
—
—
EBITDA
−9
8
36
32
Depreciation & amort.
−0
—
—
—
EBIT
−9
8
36
32
Net financials
—
—
−0
−0
Profit before tax
−9
8
36
32
Tax
−0
−2
−7
−7
Net profit
−9
6
28
25
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
Total assets
16
28
65
96
Equity
16
22
50
76
Long-term debt
0
—
—
—
Short-term debt
0
6
15
20
Total debt
—
6
15
20
Financial ratios
5-year trend
EBITDA margin
79.5%
This company
15.8%
Market median
+403% vs market
2021
2024
Equity ratio
79.1%
This company
38.2%
Market median
+107% vs market
2021
2024
Return on equity
33.3%
This company
18.4%
Market median
+81% vs market
2021
2024
Net profit margin
62.6%
This company
8.1%
Market median
+673% vs market
2021
2024
Asset turnover
0.42×
This company
1.12×
Market median
-63% vs market
2021
2024
Debt / equity
0.26×
This company
0.62×
Market median
+58% vs market
2021
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-06-01 – 2021-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (1)
TA
Tove Anna Kari Johansen Lundén
Chief Executive Officer
Chief Executive Officer
2022
Board of directors
Non-executive oversight
Name
Role
Member since
Current (1)
HI
Harald Ingvar Martin Lundén
Deputy Board Member
2022
Former (2)
EM
Eva Margareta Eljans
Deputy Board Member
2021 – 2022
AH
Anita Helena Berggren
Board of Directors
2021 – 2022
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Scandinavian Immunisation Advice Consulting AB also hold positions in
0
other companies.
Person
Role here
Other companies
Tove Anna Kari Johansen Lundén
Chief Executive Officer
0 companies
Eva Margareta Eljans
Deputy Board Member
0 companies
Harald Ingvar Martin Lundén
Deputy Board Member
0 companies
Anita Helena Berggren
Board of Directors
0 companies